Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Precision BioSciences, Inc. < Previous 1 2 3 4 Next > Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis August 09, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update August 01, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences to Participate in Upcoming August Investor Conferences July 31, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences to Report Second Quarter Results on August 1, 2024 July 29, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit July 08, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Announces its Addition to the Russell Microcap® Index July 01, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025 June 27, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness June 20, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress June 05, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences to Participate in Upcoming June Investor Conferences May 30, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) May 17, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update May 13, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement May 08, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences to Report First Quarter Results on May 13, 2024 May 07, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024 May 01, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics April 16, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update March 27, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024 March 20, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency March 06, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants March 01, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants February 29, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences February 20, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations February 13, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases February 12, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences to Effect a Reverse Stock Split February 09, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases January 09, 2024 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE December 13, 2023 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases December 04, 2023 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences to Present at Hep-DART 2023 November 30, 2023 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) November 28, 2023 From Precision BioSciences, Inc. Via Business Wire Tickers DTIL < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.